In adults with type 2 diabetes and heart disease, a weekly injection of tirzepatide lowers the risk of serious heart and kidney events—such as heart attack, stroke, hospitalization for heart failure,...
Mechanism
Synthesis from 1 study
Tirzepatide works better than dulaglutide because it helps lower blood sugar and weight more effectively, which takes pressure off the heart and kidneys. Over time, this reduces the damage that leads to heart attacks, strokes, and kidney failure.
Most probable mechanism
Tirzepatide helps the body use insulin better and lose weight, which lowers blood sugar and fat levels. This reduces strain on the heart and kidneys, making it less likely for them to get damaged over time.
Tirzepatide activates GLP-1 and GIP receptors in the pancreas, increasing insulin secretion and suppressing glucagon release in a glucose-dependent manner
Activation of central and peripheral GLP-1 and GIP receptors reduces appetite and increases satiety, leading to sustained weight loss
Improved glycemic control and reduced adiposity lower systemic inflammation, oxidative stress, and endothelial dysfunction
Reduced metabolic stress decreases glomerular hyperfiltration, arterial stiffness, and myocardial workload, slowing progression of cardiorenal damage
Evidence from Studies
Supporting (1)
Community contributions welcome
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.